Meeting
2019 ASCO Annual Meeting
Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
Authors
Satya Das
Vanderbilt University Medical Center, Nashville, TN
Satya Das , Kristen Keon Ciombor , Sigurdis Haraldsdottir , Yoanna S Pumpalova , Ibrahim Halil Sahin , Yu Shyr , Shih-Kai Chu , Emily Pei-Ying Lin , Chih-Yuan Hsu , Laura Williams Goff , Dana Backlund Cardin , Mehmet Asim Bilen , Jordan Berlin , Christina Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4116)
DOI
10.1200/JCO.2019.37.15_suppl.4116
Abstract #
4116
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya